Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma

被引:79
作者
Xia, Wen-Kai [2 ]
Liu, Zhi-Li [1 ]
Shen, Dong [1 ]
Lin, Qing-Feng [1 ]
Su, Jun [1 ]
Mao, Wei-Dong [1 ]
机构
[1] Southeast Univ, Affiliated Jiangyin Hosp, Coll Med, Dept Oncol, 163 Shoushan Rd, Jiangyin 214400, Jiangsu, Peoples R China
[2] Southeast Univ, Affiliated Jiangyin Hosp, Coll Med, Dept Nephrol, 163 Shoushan Rd, Jiangyin 214400, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Osteosarcoma; NLR; PLR; Prognosis; LYMPHOCYTE RATIO; GASTRIC-CANCER; NEUTROPHIL/LYMPHOCYTE RATIO; BREAST-CANCER; INFLAMMATION; SURVIVAL; NEUTROPHIL; SUPERIOR; SARCOMA; TUMORS;
D O I
10.1186/s12957-016-0889-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Inflammatory response markers have been proposed to predict the clinical outcomes in various cancers. The aim of this study was to explore the influence of the neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) on the prognosis of osteosarcoma. Methods: Three hundred fifty-nine patients who underwent curative surgery for osteosarcoma were enrolled from 2005 to 2010. NLR and PLR were calculated from peripheral blood cell counts taken at pre-treatment. Optimal cutoff values of NLR and PLR were determined on the basis of receiver operating characteristic curve analysis. A predictive model was established to predict the clinical outcome for overall survival, and the predictive accuracy of this model was determined by concordance index (c-index). Results: Our results showed that advanced stage and metastasis at diagnosis were significantly associated with the high NLR and PLR groups. NLR was an independent prognostic indicator for overall survival (HR = 1.80, 95 % CI = 1.35-2.41, P < 0.001) and progression-free survival (HR = 1.65, 95 % CI = 1.26-2.15, P < 0.001), except for PLR. The nomogram could perform well in the prediction of overall survival in patients with osteosarcoma (c-index 0.829). Conclusions: Our results suggest that both NLR and PLR can reflect clinical prognosis. NLR is more predictive of overall survival and progression-free survival than PLR.
引用
收藏
页数:8
相关论文
共 50 条
[41]   An Exploratory Assessment of Pre-Treatment Inflammatory Profiles in Gastric Cancer Patients [J].
Feier, Catalin Vladut Ionut ;
Muntean, Calin ;
Faur, Alaviana Monique ;
Vonica, Razvan Constantin ;
Blidari, Andiana Roxana ;
Murariu, Marius-Sorin ;
Olariu, Sorin .
DISEASES, 2024, 12 (04)
[42]   Prognostic relevance of pre-treatment inflammatory biomarkers along with other clinicopathological and treatment factors in oral cavity cancers [J].
Kothandaraman, Shri Kamakshi ;
Krishnamurthy, Arvind ;
Mittal, Saket ;
Ramshankar, Vijayalakshmi .
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (SUPPL 1) :S212-S221
[43]   Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy [J].
Ceze, N. ;
Thibault, G. ;
Goujon, G. ;
Viguier, J. ;
Watier, H. ;
Dorval, E. ;
Lecomte, T. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (05) :1305-1313
[44]   The Prognostic Model of Pre-Treatment Complete Blood Count (CBC) for Recurrence in Early Cervical Cancer [J].
Noh, Joseph J. ;
Lim, Myong Cheol ;
Kim, Moon-Hong ;
Kim, Yun Hwan ;
Song, Eun Seop ;
Seong, Seok Ju ;
Suh, Dong Hoon ;
Lee, Jong-Min ;
Lee, Chulmin ;
Choi, Chel Hun .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (09) :1-13
[45]   Pre-treatment serum lactate dehydrogenase and alkaline phosphatase as predictors of metastases in extremity osteosarcoma [J].
Marais, Leonard C. ;
Bertie, Julia ;
Rodseth, Reitze ;
Sartorius, Benn ;
Ferreira, Nando .
JOURNAL OF BONE ONCOLOGY, 2015, 4 (03) :80-84
[46]   Pre-Treatment Anemia Is a Poor Prognostic Factor in Soft Tissue Sarcoma Patients [J].
Szkandera, Joanna ;
Gerger, Armin ;
Liegl-Atzwanger, Bernadette ;
Stotz, Michael ;
Samonigg, Hellmut ;
Ploner, Ferdinand ;
Stojakovic, Tatjana ;
Leithner, Andreas ;
Pichler, Martin .
PLOS ONE, 2014, 9 (09)
[47]   Pre-treatment neutrophil to lymphocyte ratio as a prognostic marker to predict chemotherapeutic response and survival outcomes in metastatic advanced gastric cancer [J].
Cho, In Rae ;
Park, Jun Chul ;
Park, Chan Hyuk ;
Jo, Jung Hyun ;
Lee, Hyun Jik ;
Kim, Sunyong ;
Shim, Choong Nam ;
Lee, Hyuk ;
Shin, Sung Kwan ;
Lee, Sang Kil ;
Lee, Yong Chan .
GASTRIC CANCER, 2014, 17 (04) :703-710
[48]   Sanbo Scoring System, Based on Age and Pre-treatment Hematological Markers, is a Non-invasive and Independent Prognostic Predictor for Patients with Primary Glioblastomas: A Retrospective Multicenter Study [J].
Wang, Peng-fei ;
Zhang, Jianbin ;
Cai, Hong-qing ;
Meng, Zhe ;
Yu, Chun-jiang ;
Li, Shou-wei ;
Wan, Jing-hai ;
Yan, Chang-Xiang .
JOURNAL OF CANCER, 2019, 10 (23) :5654-5660
[49]   Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review [J].
Tan, Shufa ;
Zheng, Qin ;
Zhang, Wei ;
Zhou, Mi ;
Xia, Chunyan ;
Feng, Wenzhe .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[50]   The Association of Pre-treatment Peripheral Blood Markers with Survival in Patients with Pancreatic Cancer [J].
Aliustaoglu, Mehmet ;
Bilici, Ahmet ;
Seker, Mesut ;
Dane, Faysal ;
Gocun, Murat ;
Konya, Volkan ;
Ustaalioglu, Bala Basak Oven ;
Gumus, Mahmut .
HEPATO-GASTROENTEROLOGY, 2010, 57 (99-100) :640-645